Table 3.
Percentage improvement from baseline at months 4 and 6 for idiopathic hypotrichosis and chemotherapy‐induced hypotrichosis subpopulations: efficacy end points based on eyelash characteristics (intent‐to‐treat population)
| Efficacy end pointb | Time point | Idiopathic hypotrichosisa | Chemotherapy‐induced hypotrichosisa | ||||
|---|---|---|---|---|---|---|---|
| Bimatoprost (n = 179) | Vehicle (n = 59) | P‐valuec | Bimatoprost (n = 96) | Vehicle (n = 34) | P‐valuec | ||
| Upper eyelash length (mm) | Month 4 | 22·9 (177) | −4·9 (58) | < 0·01 | 28·5 (94) | 11·3 (31) | 0·02 |
| Month 6 | 26·0 (177) | −1·0 (58) | < 0·01 | 37·8 (94) | 16·3 (31) | < 0·01 | |
| Upper eyelash thickness (mm2) | Month 4 | 95·9 (150) | −7·2 (52) | < 0·01 | 180·1 (64) | 25·0 (19) | < 0·01 |
| Month 6 | 91·4 (150) | −7·7 (52) | < 0·01 | 245·9 (64) | 33·3 (19) | < 0·01 | |
| Upper eyelash darkness (intensity units)d | Month 4 | −15·7 (150) | 1·4 (52) | < 0·01 | −14·4 (65) | −5·7 (18) | 0·01 |
| Month 6 | −14·1 (150) | 1·6 (52) | < 0·01 | −16·3 (65) | −6·5 (18) | < 0·01 | |
Values are given as % (n). Bimatoprost, bimatoprost ophthalmic solution 0·03%. aMean values are presented for the idiopathic hypotrichosis subpopulation. The median is reported for the chemotherapy‐induced hypotrichosis subpopulation where the distribution of the values is skewed with a small number of very high values in percentage change from baseline from those patients who had very few or no eyelashes at baseline. bMonth 4 is the primary analysis time point. c P‐value for between‐group comparison is based on Wilcoxon rank‐sum test. dA negative change from baseline indicates darker eyelashes compared with baseline.